Celltrion stock gets a U.S. launch as operating profit rises 86.3%

Published on 10/07/2026 at 06:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Omlyclo reached the U.S. market on October 5, 2026, as the first omalizumab biosimilar. Celltrion stock also carries 45% Q2 revenue growth and a Buy consensus.

Celltrion, KR7068270008, Illustration mit AI erstellt.

Celltrion (ISIN KR7068270008) was trading at KRW 183,500 on the Korea Exchange on October 7, 2026 at 1:36 p.m. KST, up 0.60% from the previous close. The company has also brought Omlyclo, its omalizumab biosimilar, to the United States, giving the product access to the world's largest pharmaceutical market.

Omlyclo enters the U.S. market

According to Seoul Economic Daily on October 6, 2026, Celltrion launched Omlyclo in the United States on October 5, 2026. The product is the first omalizumab biosimilar to reach the U.S. market, has FDA approval for all indications held by the originator and is designated interchangeable.

Omlyclo is available in 75 milligram, 150 milligram and 300 milligram strengths. The launch also placed it on Optum's preferred commercial formulary, a distribution milestone because pharmacy benefit managers influence insurer coverage and prescribing access.

Q2 profit expands faster than sales

Health Chosun reported that Celltrion generated KRW 1.3937 trillion in consolidated revenue in Q2 2026, up 45% year over year. Operating profit reached KRW 451.8 billion, an 86.3% increase, and the operating margin was 32.4%, up 7.2 percentage points.

The contrast between revenue and operating-profit growth points to operating leverage from the product mix. Health Chosun said new products increased revenue 76% year over year and accounted for 65% of biosimilar product revenue in the quarter, while five recently launched products generated combined quarterly revenue above KRW 300 billion.

Consensus stays above the market

Investing.com lists a Buy consensus from 22 analysts, with 20 Buy ratings, 2 Holds and 0 Sells. The average 12-month price target is KRW 267,787, with a high of KRW 310,000 and a low of KRW 200,000; the average target lies 45.9 percent above the October 7 price.

For investors, the commercial rollout and the Q2 margin provide two separate tests for the growth story. The launch must convert formulary access into prescriptions, while the 32.4% operating margin shows how strongly newer products are already influencing reported profitability.

Celltrion stock trades below yearly high

Celltrion stock was trading at KRW 183,500 on October 7, 2026. Its 52-week range was KRW 158,500 to KRW 239,047.62, placing the quote below the yearly high while the market capitalization stood at KRW 42.1 trillion.